AR and prostate carcinoma: Indeed, androgen ablation by an inhibitor of androgen biosynthesis, abiraterone acetate, and by enzalutamide, an AR antagonist that prevents nuclear translocation and chromatin binding, extend survival of prostate cancer patients.